Bioactive Bone Graft Substitute

KAINOS+ was developed through extensive research conducted on bioceramic bone substitution materials. Studies have proven the effectiveness of the bioactive properties of KAINOS+ for inducing new bone formation. With its unique combination of chemo-physical and structural properties KAINOS+ becomes fully integrated in the natural remodeling process and is completely resorbed while being simultaneously replaced by new bone, making it the ideal bone graft substitute.

KAINOS+ is a biphasic mixture of hydroxyapatite and tricalcium phosphate (60%; 40%, respectively) that has a unique structure of micro (<10µm) and macro pores (300 – 600µm) due to its proprietary production process. Via the HA component, the osteoconducive matrix is present for the appropriate time to allow osteogenic cells to “dock” at the scaffold. And by the TCP component a high saturation of calcium ions is guaranteed. Further the micro pores (30% of the overall pore volume; total porosity: 70%) allow the physiological fluids to diffuse throughout the ceramic implant. A result is the precipitation of bone-like apatite crystals, providing additional “anchor points” for bone cells. The micro/macro pore structure represents a crucial feature of the concept of bioactivity. Bone in-growth occurs at the bone-ceramic interface as well as within the entire implant structure - until KAINOS+ is completely transformed by this controlled and balanced process.

When KAINOS+ is used in conjunction with spinal implants such as cages, the fusion rate is comparable to that of autogenic graft material. New bone formation is usually detected within a few weeks, and after three months accounts for more than 30% to 40% of the ceramic implant, and nearly 100% after six months. In addition to biocompatibility, the added benefit of using KAINOS+ is the elimination of additional surgery and donor site complications associated with harvesting autogenic bone grafts.

Indications

Fusion
Scoliosis
Osteotomy
Trauma
Vertebrectomy

Specific Advantages

Stimulates osteogenic cells
Inducing optimal new bone formation through a novel bioactive platform

Rapid bone re-building and healing
Via resorption/remodeling process transformed within  months

Solid bony fusion
Consolidated and close bone-to-implant contact at the interface.

Excellent micro/macro porosity
Porosity characteristics remain even when compacted

Can be easily combined with autograft or growth factors
Extending surgical options

Completely synthetic, biocompatible and pathogen free
No known inflammation or immunological reactions

Time and cost effective – ready for use
Reducing donor site complications and overall procedure time